Few UK "Promising Innovative Medicine" Holders Seek Joint MHRA/NICE Advice – Rawlins

MHRA chief says too few drug makers granted PIM designation on the basis of early clinical data are making use of joint consultations with the agency and the cost-effectiveness watchdog NICE.